• 1
    Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65: 21412148.
  • 2
    Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009; 85: 256258.
  • 3
    Pandori M, Barry PM, Wu A et al. Mosaic Penicillin-Binding Protein2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53: 40324034.
  • 4
    Ohnishi M, Watanabe Y, Ono E et al. Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother 2010; 54: 10601067.
  • 5
    Ochiai S, Ishiko H, Yasuda M, Deguchi T. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with susceptibilities to oral cephalosporins. J Clin Microbiol 2008; 46: 18041810.
  • 6
    Plourde PJ, Tyndall M, Agoki E et al. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. J Infect Dis 1992; 166: 919922.
  • 7
    Unemo M, Golparian D, Syversen G, Vestrheim F, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15, pii: 19721.
  • 8
    Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58: 683687.
  • 9
    Unemo M, Olcén P, Jonasson J, Fredlund H. Molecular typing of Neisseria gonorrhoeae isolates by pyrosequencing of highly polymorphic segments of the porB Gene. Clin Microbiol Infect 2004; 42: 29262934.
  • 10
    Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007; 51: 21172122.
  • 11
    Lee SG, Lee H, Jeong SH et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010; 65: 669675.
  • 12
    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Expert rules 2010. Available at: Version 1.1 (last accessed 27 April 2010).
  • 13
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-S18, Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
  • 14
    Mavroidi A, Tzouvelekis LS, Kyriakis KP, Avgerinou H, Daniilidou M, Tzelepi E. Multidrug-resistant strains of Neisseria gonorrhoeae in Greece. Antimicrob Agents Chemother 2001; 45: 26512654.
  • 15
    Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189: 14971505.
  • 16
    Starnino S, Stefanelli P, Neisseria gonorrhoeae Italian Study Group. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother 2009; 63: 12001204.
  • 17
    Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal restriction patterns produced by pulsed field gel electrophoresis: criteria for bacterial strains typing. J Clin Microbiol 1995; 33: 22332239.
  • 18
    Ito M, Deguchi T, Mizutani KS et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005; 49: 137143.
  • 19
    Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007; 51: 31113116.
  • 20
    Rehman S, Khan A, Amanullah, Akhter K. Clinical efficacy of the various drugs used in the treatment of gonorrhoeae. J Ayub Med Coll Abbottabad 2009; 21: 2830.
  • 21
    Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13: 12751277.
  • 22
    Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010; 86: 454460.
  • 23
    Whiley DM, Goire N, Lambert SB et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother 2010; 65: 16151618.
  • 24
    Tzelepi E, Daniilidou M, Miriagou V, Siatravani E, Pavlidou E, Flemetakis A. Cluster of multidrug-resistant Neisseria gonorrhoeae with reduced susceptibility to the newer cephalosporins in Northern Greece. J Antimicrob Chemother 2008; 62: 637639.
  • 25
    Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2010; 59: 1110. Erratum in: MMWR Recomm Rep 2011; 60: 18.
  • 26
    Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2009; 20: 453457.
  • 27
    Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonorrhoea – is dual therapy the way forward? Int J STD AIDS 2007; 18: 647648.
  • 28
    Whiley DM, Jacobsson S, Tapsall JW, Nissen MD, Sloots TP, Unemo M. Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother 2010; 65: 25432547.